Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists

Journal of Medicinal Chemistry

Volumn 40, Issue 13, 1997, Pages 2064-2084

  Xue, Chu Biao ^a   Wityak, John ^a   Sielecki, Thais M ^a   Pinto, Donald J ^a   Batt, Douglas G ^a   Cain, Gary A ^a   Sworin, Michael ^a   Rockwell, Arlene L ^a   Roderick, John J ^a   Wang, Shuaige ^a   Orwat, Michael J ^a   Frietze, William E ^a   Bostrom, Lori L ^a   Liu, Jie ^a   Higley, C Anne ^a   Rankin, F Wayne ^a   Tobin, A Ewa ^a   Emmett, George ^a   Lalka, George K ^a   Sze, Jean Y ^a   Di Meo, Susan V ^a   Mousa, Shaker A ^a   Thoolen, Martin J ^a   Racanelli, Adrienne L ^a   Hausner, Elizabeth A ^a   Reilly, Thomas M ^a   DeGrado, William F ^a   Wexler, Ruth R ^a   Olson, Richard E ^a   more..

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 [2 [3 (4 FORMAMIDINOPHENYL) 2 ISOXAZOLIN 5 YL]ACETAMIDO]PROPIONIC ACID; ADENOSINE DIPHOSPHATE; CARBAMIC ACID; CARBOXYLIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; ISOXAZOLINE DERIVATIVE; S 1762; SB 208651; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BABOON; DOG; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RHESUS MONKEY; STEREOCHEMISTRY; THROMBOCYTE;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PLATELETS; DOGS; DRUG DESIGN; FEMALE; ISOXAZOLES; MACACA MULATTA; MALE; MODELS, CHEMICAL; PAPIO; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 14444267771     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960799i     Document Type: Article

References (57)

1. Olson, R. E.; Wityak, J.; Xue, C.-B.; Sielecki, T. M.; Cain, G. A.; Mousa, S. A.; Thoolen, M. J.; Racanelli, A. L.; Hausner, E. A.; Reilly, T. M.; DeGrado, W. F.; Wexler, R. R. The Discovery of DMP 754, an Orally Active Isoxazoline GPIIb/IIIa Antagonist. 211th American Chemical Society National Meeting, March 24-28, 1996; MEDI 250.
2. Xue, C.-B.; Wityak, J.; Sielecki, T. M.; Cain, G. A.; Liu, J.; Bostrom, L. L.; DiMeo, S. V.; Higley, C. A.; Lalka, G. K.; Tobin, A. E.; Frietze, W. E.; Emmett, G.; Sze, J. Y.; Mousa, S. A.; Thoolen, M. J.; Reilly, T. M.; DeGrado, W. F.; Olson, R. E; Wexler, R. R. Synthesis and Pharmacology of Orally Active, Isoxazoline Glycoprotein IIb-IIIa Receptor Antagonists. 211th American Chemical Society National Meeting, March 24-28, 1996; MEDI 132.
3. Leonard, E. F.; Turitto, V. T.; Vroman, L. Blood in Contact with Natural and Artificial Surfaces. Ann. N.Y. Acad. Sci. 1987, 516, 1-688.
4. Maseri, A.; Chierchia, S.; Davies, G. Pathophysiology of Coronary Occlusion in Acute Infarction. Circulation 1986, 73, 233-239.
5. Harker, L. A. Clinical Trials Evaluating Platelet-Modifying Drugs in Patients with Atherosclerotic Cardiovascular Disease and Thrombosis. Circulation 1986, 73, 206-223.
6. Haerem, J. W. Platelet Aggregates in Intramyocardial Vessels of Patients Dying Suddenly and Unexpectedly from Coronary Artery Disease. Atherosclerosis 1972, 15, 199-213.
7. Phillips, D. R.; Charo, I. F.; Parise, L. V.; Fitzgerald, L. A. The Platelet Membrane Glycoprotein IIb-IIIa Complex. Blood 1988, 71, 831-843.
8. Colman, R. W.; Marder, V. J.; Salzman, E. W.; Hirsh, J. Overview of Hemostasis. In Hemostasis and Thrombosis; Basic Principles and Clinical Practices, 2nd ed.; Colman, R. W., Hirsh, J., Marder, V. J., Salzman, E. W., Eds.; Lippincott Publishers: Philadelphia, 1987; pp 3-17.
9. Faulds, D.; Sorkin, E. M. Abciximab (c7E3 Fab). Drugs 1994, 48, 583-598.
10. Tcheng, J. E.; Harrington, R. A.; Kottke-Marchant, K.; Kleiman, N. S.; Ellis, S. G.; Kereiakes, D. J.; Mick, M. J.; Navetta, F. I.; Smith, J. E.; Worley, S. J.; Miller, J. A.; Joseph, D.; Sigmon, K. N.; Kitt, M. M.; Du Mee, C. P.; Califf, R. M.; Topol, E. J.; for the IMPACT Investigators. Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention. Circulation 1995, 91, 2151-2157.
11. Barrett, J. S.; Murphy, M. G.; Peerlink, K.; De Lepeleire, I.; Gould, R. J.; Panebianco, D.; Hand, E.; Deckmyn, H.; Vermylen, J.; Arnout, J. Pharmacokinetics and Pharmacodynamics of MK-383, a Selective, Non-Peptide Platelet Glycoprotein-IIb/IIIa Receptor Antagonist, in Healthy Men. Clin. Pharmacol. Ther. 1994, 56, 377-388.
12. Théroux, P.; Kouz, S.; Roy, L.; Knudtson, M. L.; Diodati, J. G.; Marquis, J.-F.; Nasmith, J.; Fung, A. Y.; Boudreault, J.-R.; Delage, F.; Dupuis, R.; Kells, C.; Bokslag, M.; Steiner, B.; Rapold, H. J.; on Behalf of the Investigators. Platelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina. Circulation 1996, 94, 899-906.
13. Hawiger, J.; Kloczewiak, M.; Bednarek, M.; Timmons, S. Platelet Receptor Recognition Domain on alpha Chain of Human Fibrinogen: Structure-Function Analysis. Biochemistry 1989, 28, 2909-2914.
14. Ruoslathi, E.; Pierschbacher, M. D. New Perspectives in Cell Adhesion: RGD and Integrins. Science 1987, 238, 491-497.
15. Hawiger, J.; Timmons, S.; Kloczewiak, M.; Strong, D. D.; Doolittle, R. F. Gamma and Alpha Chains of Human Fibrinogen Posess Sites Reactive with Human Platelet Receptors. Proc. Natl. Acad. Sci. U.SA. 1982, 79, 2086.
16. Kloczewiak, M.; Timmons, S.; Lukas, T. J.; Hawiger, J. Platelet Receptor Recognition Site on Human Fibrinogen: Synthesis and Structure-Function Relationship of Peptides Corresponding to the Carboxy-Terminal Segment of the Gamma Chain. Biochemistry 1984, 23, 1767.
17. Farrell, D. H.; Thiagarajan, P.; Chung, D. W.; Davie, E. W. Role of Fibrinogen a and y Chain Sites in Platelet Aggregation. Proc. Natl. Acad. Sci. U.SA. 1992, 89, 10729-10732.
18. Wityak, J.; Sielecki, T. M.; Pinto, D. J.; Sze, J. Y.; Liu, J.; Tobin, A. E.; Wang, S.; Jiang, B.; Emmett, G.; Ma, P.; Mousa, S. A.; Ma, P.; Olson, R. E.; Wexler, R. R. The Discovery of Potent Isoxazoline Glycoprotein IIb/IIIa Receptor Antagonists. J. Med. Chem. 1997, 40, 50-60.
19. Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T.-C.; Gould, R. J. Non-peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors. J. Med. Chem. 1992, 35, 4640-4642.
20. Klein, S. I.; Molino, B. F.; Czekaj, M.; Dener, J. S.; Leadley, R. J.; Sabatino, R.; Dunwiddie, C. T.; Chu, V. Non-Peptide Fibrinogen Receptor Antagonists Based Upon a 4-Substituted Piperidine Scaffold. Bioorg. Med. Chem. Lett. 1996, 6, 1403-1408.
21. Bovy, P. R.; Tjoeng, F. S.; Rico, J. G.; Rogers, T. E.; Landmark, R. J.; Zablocki, J. A.; Garland, R. B.; McMackins, D. E.; Dayringer, H.; Tóth, M. V.; Zupec, M. E.; Rao, S.; Panzer-Knodle, S. G.; Nicholson, N. S.; Salyers, A.; Taite, B. B.; Herin, M.; Miyano, M.; Feigen, L. P.; Adams, S. P. Design of Orally Active, Non-Peptide Fibrinogen Receptor Antagonists. An Evolutionary Process from the RGD Sequence to Novel Anti-platelet Aggregation Agents. Bioorg. Med. Chem. 1994, 2, 881-895.
22. Jackson, S.; DeGrado, W.; Dwivedi, A.; Parthasarathy, A.; Higley, A.; Krywko, J.; Rockwell, A.; Markwalder, J.; Wells, G.; Wexler, R.; Mousa, S.; Harlow, R. Template-Constrained Cyclic Peptides: Design of High-Affinity Ligands for GPIIb/IIIa. J. Am. Chem. Soc. 1994, 116, 3220-3230.
23. Ku, T. W.; Ali, F. E.; Barton, L. S.; Bean, J. W.; Bondinell, W. E.; Burgess, J. L.; Callahan, J, F.; Calvo, R. R.; Chen, L.; Eggleston, D. S.; Gleason, J. G.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Karash, C. B.; Keenan, R. M.; Kopple, K. D.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Peishoff, C. E.; Samanen, J. M.; Uzinskas, I.; Venslavsky, J. W. Direct Design of a Potent Non-Peptide Fibrinogen Receptor Antagonist Based on the Structure and Conformation of a Highly Constrained Cyclic RGD Peptide. J. Am. Chem. Soc. 1993, 115, 8861-8862.
24. Zablocki, J. A.; Miyano, M.; Garland, R. B.; Pireh, D.; Schretzman, L.; Rao, S. N.; Lindmark, R. J.; Panzer-Knodle, S. G.; Nicholson, N. S.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based upon the Arg-Gly-Asp Sequence of Fibrinogen. A Proposal of the Nature of the Binding Interaction Between the Arg-Guanidine of RGDX Mimetics and the Platelet GP IIb-IIIa Receptor. J. Med. Chem. 1993, 36, 1811-1819.
25. Stilz, H. U.; Jablonka, B.; Just, M.; Knolle, J.; Paulus, E. F.; Zoller, G. Discovery of an Orally Active Non-Peptide Fibrinogen Receptor Antagonist. J. Med. Chem. 1996, 3, 1675-1680.
26. Cadroy, Y.; Houghten, R. A.; Hanson, S. R. RGDV Peptide Selectively Inhibits Platelet-Dependent Thrombus Formation In Vivo. J. Clin. Invest. 1989, 84, 939-944.
27. Davies, S. G.; Ichihara, O. Asymmetric Synthesis of R-β-Amino Butanoic Acid and S-β-Tyrosine: Homochiral Lithium Amide Equivalents for Michael Additions to α,β-Unsaturated Esters. Tetrahedron: Asymmetry 1991, 2, 183-186.
28. Xue, C.-B.; Rafalski, M.; Roderick, J.; Eyermann, C. J.; Mousa, S.; Olson, R. E.; DeGrado, W. F. Design, Synthesis and In Vitro Activities of a Series of Benzimidazole/Benzoxazole Glycoprotein IIb/IIIa Inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 339-344.
29. Sakai, N.; Ohfune, Y. Total Synthesis of Galantin I. Acid-Catalyzed Cyclization of Galantinic Acid. J. Am. Chem. Soc. 1992, 114, 998-1010.
30. 2 at a flow rate of 1.0 mL/min, and a pressure of 150 atm. Detection was by UV at 280 nm.
31. Godfrey, A. G.; Ganem, B. Ready Oxidation of Halides to Aldehydes Using Trimethylamine N-Oxide in Dimethylsulfoxide. Tetrahedron Lett. 1990, 37, 4825-4826.
32. Rai, R.; Katzenellenbogen, J. A. Guanidinophenyl-Substituted Enol Lactones as Selective, Mechanism-Based Inhibitors of Trypsin-like Serine Proteases. J. Med. Chem. 1992, 35, 4150-4159.
33. Kim, K. S.; Qian, L. Improved Method for the Preparation of Guanidines. Tetrahedron Lett. 1993, 34, 7677-7680.
34. Shin, C.-G.; Obara, T.; Segami, S.; Yonezawa, Y. Convenient Synthesis and Reactions of the Two Kinds of Basic α-Dehydroamino Acid Derivatives. Tetrahedron Lett. 1987, 28, 3827-3830.
35. Bernatowicz, M. S.; Wu, Y.; Matsueda, G. R. Urethane Protected Derivatives of 1-Guanylpyrazole for the Mild and Efficient Preparation of Guanidines. Tetrahedron Lett. 1993, 34, 3389-3392.
36. Le Gall, T.; Darganzanli, G.; Grée, R.; Millet, J.; Sepulchre, C.; Bellamy, F. Synthesis and Biological Evaluation of new 5-H-PETE Analogs. Bioorg. Med. Chem. Lett. 1994, 4, 253-256.
37. For in vitro assay protocols, see: Mousa, S. A.; Bozarth, J. M.; Forsythe, M. S.; Lorelli, W.; Ramachandran, N.; Jackson, S.; De Grado, W. F.; Reilly, T. M. Antiplatelet Efficacy and Specificity of DMP 728, A Novel Platelet GPIIb/IIIa Receptor Antagonist. Cardiology 1993, 83, 374-382.
38. Zablocki, J. A.; Tjoeng, F. S.; Bovy, P. R.; Miyano, M.; Garland, R. B.; Williams, K.; Schretzman, L.; Zupec, M. E.; Rico, J. G.; Lindmark, R. J.; Toth, M. V.; McMackins, D. E.; Adams, S. P.; Panzer-Knodle, S. G.; Nicholson, N. S.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. A Novel Series of Orally Active Antiplatelet Agents. Bioorg. Med. Chem. 1995, 3, 539-551.
39. For in vivo assay protocols, see: Mousa, S. A.; DeGrado, W. F.; Mu, D.-X.; Kapil, R. P.; Lucchesi, B. R.; Reilly, T. M. Oral Antiplatelet, Antithrombotic Efficacy of DMP 728, a Novel Platelet GPIIb/IIIa Antagonist. Circulation 1996, 93, 537-543.
40. Milner-White, E. J. Predicting the Biologically Active Conformations of Short Polypeptides. Trends Pharmacol. Sci. 1989, 10, 70-74.
41. Hruby, V. J. Design of Peptide Hormone and Neurotransmitter Analogues. Trends Pharmacol. Sci. 1985, 6, 259-262.
42. Wagner, G.; Horn, H.; Richter, P.; Vieweg, H.; Lischke, I.; Kazmirowski, H.-G. Synthesis of Antiproteolytically Active Nα-Sulfonylated Amidinophenylalanamides. Pharmazie 1981, 36, 597-603
43. McDowell, R. S.; Blackburn, B. K.; R. S.; Gadek, T. R.; McGee, L. R.; Rawson, T.; Reynolds, M. E.; Robarge, K. D.; Somers, T. C.; Thorsett, E. D.; Tischler, M.; Webb, R. R. II; Venuti, M. C. From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-Peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepine Scaffold. J. Am. Chem. Soc. 1994, 116, 5077-5083.
44. Alig, L.; Edenhofer, A.; Hadváry, P.; Hürzeler, M.; Knopp, D.; Müller, M.; Steiner, B.; Trzeciak, A.; Weller, T. Low Molecular Weight, Non-Peptide Fibrinogen Receptor Antagonists. J. Med. Chem. 1992, 35, 4393-4407.
45. Perrin, D. D.; Dempsey, B.; Sergeant, E. P. pKa Prediction for Organic Acids and Bases; Chapman and Hall: London, 1981.
46. Egbertson, M. S.; Chang, C. T.-C.; Duggan, M. E.; Gould, R. J.; Halczenko, W.; Hartman, G. D.; Laswell, W. L.; Lynch, J. J., Jr.; Lynch, R. J.; Manno, P. D.; Naylor, A. M.; Prugh, J. D.; Ramjit, D. R.; Sitko, G. R.; Smith, R. S.; Turchi, L. M.; Zhang, G. Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp. J. Med. Chem. 1994, 37, 2537-2551.
47. Mousa, S. A.; Bozarth, J.; Forsythe, M.; Xue, C.-B.; Wityak, J.; Olson, R.; Thoolen, M.; Reilly, T. Discovery of Novel Orally Active Non-Peptide Antiplatelet GPIIb/IIIa Antagonist, DMP 754: Comparative Platelet Binding Affinity Profiles with DMP 728 and c7E3. Thromb. Haemostasis 1997, in press (abstract).
48. Mousa, S. A.; Forsythe, M.; Lorelli, W.; Bozarth, J.; Xue, C.-B.; Wityak, J.; Sielecki, T. M.; Olson, R. E.; DeGrado, W.; Kapil, R.; Hussain, M.; Wexler, R.; Thoolen, M. J.; Reilly, T. M. Novel Non-Peptide Antiplatelet GPIIb/IIIa Receptor Antagonist, DMP 754: Receptor Binding Affinity & Specificity. Coron. Artery Dis. 1996, 7, 767-774.
49. Mousa, S. A.; Bozarth, J., Forsythe, M.; Wityak, J.; Reilly, T.; Mu, D.-X. Intravenous and Oral Antiplatelet/Antithrombotic Efficacy and Specificity of XR300, a Novel Non-Peptide Platelet GPIIb/IIIa Antagonist. Circulation 1996, 94, 1-99, Abstract 0569.
50. Racanelli, A. L.; Kapil, R.; Mousa, S. A.; Reilly, T. M.; Thoolen, M. J. Oral Antiplatelet Effects of DMP 754 in Dogs and Non-Human Primates. Circulation 1996, 94, 1-98, Abstract 0565.
51. αt-Boc-2,4-Diaminobutyric Acid (DBR) Derivatives Suitable for Solid Phase Peptide Synthesis. Org. Prep. Proc. Int. 1990, 22, 597-603.
52. Baker, W.; Ollis, W. D. Attempted Syntheses of Penicillin Homologues. J. Chem. Soc. 1949, 345-349.
53. Engel, M. R. Sur la Formation d'Acide Amidobutyrique par Fixation Directe d'Ammoniaque sur l'Acide Crotonique. Bull. Soc. Chim. Fr. 1988, 50, 102-104.
54. Elkasaby, M. A.; Salem, M. A. I. Synthesis of New Isoxazoles from Isoxazolines, Chalkones, Chalkone Dibromides, Epoxides and Acetylated Ketoximes & Their Conversion into Novel Heterocycles. Indian J. Chem. 1980, 19B, 571-575.
55. Ikeda, Y.; Ueki, Y.; Kishimoto, H.; Nishihara, T.; Kamikawa, Y. Preparation of Peptides Containing 2,3-Diaminopropionic Acid Derivatives Having Selective Affinity to Cell Adhesion Activating Protein Receptors. World Pat. Appl. 9511228, April 27, 1995.
56. Hartman, G. D.; Prugh, J. D.; Egbertson, M. S.; Duggan, M. E.; Hoffman, W. Novel Fibrinogen Receptor Antagonists and Preparation Thereof. World Pat. Appl. 9408577, April 28, 1994.
57. The isourea was prepared using the method described for the preparation of the cyclohexyl derivative; see: Mathias, L. J. Esterification and Alkylation Reactions Employing Isoureas. Synthesis 1979, 561-576.